We do not allow the unauthorized collection of e-mail addresses listed on our website.Persons engaging in unauthorized collection with e-mail address collection programs or other technical devices will be subject to criminal prosecution in accordance with the Act on Information & Communications Network Utilization and Information Protection.
RNAi platform development
Lead compound discovery
Pharmacological research on OliX RNAi compounds for respiratory and neurological diseases
Pharmacological research on OliX RNAi compounds for ocular diseases
Testing efficacy of oligonucleotide therapeutics using animal models
Develop analytical methods for therapeutic candidates to determine purity and stability in support of nonclinical and clinical studies
Develop bioanalytical methods to quantitate therapeutic candidates in biological matrices for pharmacokinetic and toxicokinetic (PK/TK) studies
Manage manufacturing, analytics and quality of therapeutic candidates
Conduct safety evaluation and toxicokinetic assessment of therapeutic candidates through nonclinical studies
Establish clinical development plans for therapeutic candidates and conduct clinical studies
Mid to Long-term Business Goals/Strategy Planning
Make official announcements about business contents, financial condition, business performance etc.
Stabilize Internal Accounting Control System
IT Infrastructure Management
HR Policy/System Establishment, Organization/Job Design
Performance Management, Employee Welfare
Prevent, respond, handle legal disputes
Provide risk management and compliance support
Develop IP strategies for core technologies
Verify pharmaceutical R&D processes and results
Ensure product to meet the established quality standards
Develop/Maintain Client Relationships
Execute Licensing Agreements
New Business/Strategy Planning
Provide investment information in a timely manner to increase company value
Promote management activities and establish internal/external communication strategies
Create positive corporate culture through various in-house activities and employee education
|OliX Pharmaceuticals Enters Agreement with Pharmaron|
|Date : 2022-03-22 View : 376|
OliX Pharmaceuticals Enters Agreement with Pharmaron to Advance Non-clinical Toxicology Testing for Hepatitis B Candidate OLX703A
- Previous non-clinical pharmacology study demonstrated substantial reduction in serum markers of HBV
SUWON, Republic of Korea, Oct. 19, 2021 – OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company has selected Pharmaron, a leading contract research organization based in China, to conduct non-clinical toxicity studies to evaluate the safety of OLX703A, OliX’s investigational therapeutic for hepatitis B (HBV).
OLX703A utilizes GalNAc-asiRNA technology and is designed to inhibit all HBV transcripts and proteins, including hepatitis B surface antigen (HBsAg). It allows suppression of HBV replication and has been confirmed to be functional against all major HBV genotypes and subtypes.
Last June, OliX conducted a non-clinical pharmacology study of OLX703A and observed an approximately 100-fold reduction of key markers in serum associated with HBV, including s-antigen, e-antigen, and HBV DNA. According to the Company, these key results are comparable to the published preclinical data of competing therapeutics. Active pharmaceutical ingredient (API) production of OLX703A for preclinical and clinical studies is currently underway with LGC BioSearch Technologies.
“We are pleased to work with Pharmaron to advance non-clinical toxicity studies for OLX703A given their extensive research and development experience in China and the broader Asia region,” said Dong Ki Lee, Ph.D., founder and chief executive officer of OliX Pharmaceuticals. “We are encouraged by our progress in developing therapeutics for liver disease based on our GalNAc-asiRNA technology and look forward to advancing OLX703A into clinical trials as quickly as possible.”
|Prev||OliX Pharmaceuticals to Conduct One-on-One Meetings at BIO-Europe Digital 2021 Conference|
|Next||Hansoh Pharma and OliX Pharmaceuticals Enter into Licensing and Collaboration Agreement|